Abstract: Objective By means of detecting serum CD147 level, we investigate the relationship of serum CD147 level with early clinical outcome of transient ischemic attack(TIA).Methods A total of 135 TIA patients, who were selected in Xuzhou Medical University Affiliated Hospital from Jan 2016 to Oct 2016, were enrolled in this study. At the same time, the TIA group was divided into low risk group (45 cases), middle risk group (69 cases) and high risk group (21 cases) according to ABCD3 score. TIA patients were followed up on the 2nd, 7th, 30th and 90th day since the hospitalization date respectively. The level of serum CD147 were detected by enzyme-linked immunosorbent assay (ELISA). SPSS 19.0 statistical software was run, to analyze the serum CD147 level with low, middle, high risk group and early clinical outcome after TIA. Results There was significant difference in serum CD147 level in patients with low, middle and high risk groups (P < 0.05), and the serum CD147 level increased with the increase of risk level in TIA patients. In the 2nd, 7th, 30th and 90th day of follow-up, the serum CD147 (8.65±2.02) ng/mL of the positive event group was significantly higher than that in the negative event group (5.73±1.82) ng/mL (P<0.05). Comparison of the incidence of cerebral infarction in patients with different risk levels in TIA group， The incidence of cerebral infarction in high-risk groups was the highest, followed by the middle critical group and the lowest in the low-risk group, indicating that with the upgrade in risk level, the morbidity of cerebral infarction after TIA also becomes higher. Conclusion Serum CD147 level was positively correlated with TIA risk grade and incidence of early stroke after TIA